CardioKinetix, based in Menlo Park, Calif., is pioneering the catheter-based Parachute Ventricular Partitioning Device for heart failure. Privately held, the company is backed by SV Life Sciences, New Leaf Venture Partners, U.S. Venture Partners, JPMorgan Partners, Panorama Capital, H&Q Healthcare Investors, and H&Q Life Sciences Investors.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/28/13 | $23,000,000 | Series E-2 |
H&Q Healthcare Investors H&Q Life Sciences Investors JPMorgan Partners New Leaf Venture Partners Panorama Capital U.S. Venture Partners | undisclosed |
| 12/09/14 | $50,000,000 |
Edwards LifeSciences Lexington Partners New Leaf Venture Partners Panorama Capital Tekla Capital Management US Venture Partners | undisclosed |
